PMID- 32104029
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220413
IS  - 1178-7007 (Print)
IS  - 1178-7007 (Electronic)
IS  - 1178-7007 (Linking)
VI  - 13
DP  - 2020
TI  - Sera Anti-P53 Antibody Provides New Information Which Explains the Link Between 
      Diabetes and Cancer.
PG  - 325-331
LID - 10.2147/DMSO.S213731 [doi]
AB  - INTRODUCTION: Abnormalities in glucose metabolism in diabetic patients may lead 
      to an increased risk of certain cancers. Epidemiological studies and 
      meta-analysis have shown that factors such as gender, age, obesity, and insulin 
      resistance are related to cancer incidence. The anti-p53 antibody is a known 
      cancer marker due to tumor-associated p53 accumulation. Many studies have aimed 
      to unravel the link between diabetes and cancer. Here, we aimed to elucidate the 
      impact of diabetes on malignancies by analyzing anti-p53 antibody in sera of type 
      2 diabetes mellitus (T2DM) patients. MATERIALS AND METHODS: We conducted an 
      observational study with a cross-sectional design. A total of 149 subjects 
      comprised of 78 T2DM patients (32 with cancer risk and 46 subjects without cancer 
      risk), 51 T2DM patients with cancer, and 20 healthy subjects as controls from 
      multisites. The anti-p53 antibody was measured by enzyme-linked immunosorbent 
      assay, while HbA1c was measured using the NGSP standardized method. RESULTS: We 
      observed an 8.3-fold (p<0.05) increase of anti-p53 antibody in the sera of T2DM 
      patients and a 24-fold increase (p<0.001) in T2DM patients with cancer compared 
      to healthy subjects. The anti-p53 antibodies significantly increased almost three 
      times (p<0.05) in T2DM patients with cancer (0.72 U/mL+/-0.20) compared to T2DM 
      patients (0.25 U/mL+/-0.05). Meanwhile, this antibody was almost undetectable in 
      healthy subjects as a control group (0.03 U/mL+/-0.03). The anti-p53 antibody level 
      was higher in T2DM with cancer risk patients. However, we did not find a 
      significant difference for it in T2DM without cancer risk patients (0.19 
      U/mL+/-0.03) and T2DM with cancer risk patients (0.29 U/mL+/-0.08). Multivariate 
      regression analysis showed that T2DM with cancer was the only one independent 
      factor (beta=0.218, p=0.019) that could predict the increase of anti-p53 
      antibody, controlled by age, gender, BMI, DM duration, and HbA1c. CONCLUSION: Our 
      results showed that anti-p53 antibody almost not detected in healthy subjects, 
      but 8.3-fold increase in the sera of T2DM patients and 24-fold increase in T2DM 
      patients with cancer. Therefore, this biomarker provides new information which 
      explains the link between diabetes and cancer.
CI  - (c) 2020 Sauriasari et al.
FAU - Sauriasari, Rani
AU  - Sauriasari R
AUID- ORCID: 0000-0001-7861-4369
AD  - Faculty of Pharmacy, Universitas Indonesia, Depok, Indonesia.
FAU - Sekar, Andisyah Putri
AU  - Sekar AP
AD  - Faculty of Pharmacy, Universitas Indonesia, Depok, Indonesia.
FAU - Aisyah, Nurul
AU  - Aisyah N
AD  - Faculty of Pharmacy, Universitas Indonesia, Depok, Indonesia.
FAU - Syahdi, Rezi Riadhi
AU  - Syahdi RR
AD  - Faculty of Pharmacy, Universitas Indonesia, Depok, Indonesia.
FAU - Matsuura, Eiji
AU  - Matsuura E
AUID- ORCID: 0000-0003-1681-0684
AD  - Neutron Therapy Research Center, Collaborative Research Center for OMIC & 
      Department of Cell Chemistry, Okayama University Graduate School of Medicine, 
      Dentistry, and Pharmaceutical Sciences, Okayama University, Okayama, Japan.
LA  - eng
PT  - Journal Article
DEP - 20200211
PL  - New Zealand
TA  - Diabetes Metab Syndr Obes
JT  - Diabetes, metabolic syndrome and obesity : targets and therapy
JID - 101515585
PMC - PMC7023868
OTO - NOTNLM
OT  - P53
OT  - anti-p53 antibodies
OT  - cancer
OT  - diabetes mellitus
COIS- The authors report no conflicts of interest in this work.
EDAT- 2020/02/28 06:00
MHDA- 2020/02/28 06:01
PMCR- 2020/02/11
CRDT- 2020/02/28 06:00
PHST- 2019/04/28 00:00 [received]
PHST- 2020/01/03 00:00 [accepted]
PHST- 2020/02/28 06:00 [entrez]
PHST- 2020/02/28 06:00 [pubmed]
PHST- 2020/02/28 06:01 [medline]
PHST- 2020/02/11 00:00 [pmc-release]
AID - 213731 [pii]
AID - 10.2147/DMSO.S213731 [doi]
PST - epublish
SO  - Diabetes Metab Syndr Obes. 2020 Feb 11;13:325-331. doi: 10.2147/DMSO.S213731. 
      eCollection 2020.